Open Access<p>Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion</p>
Author(s) -
Sojung Han,
Hye Won Lee,
Jun Yong Park,
Seung Up Kim,
Sang Hoon Ahn,
KwangHyub Han,
Jinsil Seong,
Jong Yun Won,
Dai Hoon Han
Publication year - 2020
Publication title -
journal of hepatocellular carcinoma
Language(s) - English
Resource type - Journals
ISSN - 2253-5969
DOI - 10.2147/jhc.s276528
Subject(s) - medicine , hepatocellular carcinoma , gastroenterology , sorafenib , chemoradiotherapy , oncology , radiation therapy , surgery
Molecular-targeted agents are acceptable standards to treat advanced-stage hepatocellular carcinoma (HCC), however, their therapeutic benefit, ie, sorafenib, was significantly offset in case of major vessel invasion. Liver-directed concurrent chemo-radiotherapy (LD-CCRT) provided favorable outcomes in terms of survivals and tumor shrinkage, so, we appraised its long-term therapeutic efficacy.